Einfluss von VEGF-Inhibitoren auf das Hornhautendothel bei Injektion in die Vorderkammer am Modell des Schweineauges

详细信息    查看全文

• 作者：A. Wilhelm ; R. Sietmann ; U. Wilhelm ; T. Hammer
• 关键词：Rubeosis iridis ; Neovaskularisationsglaukom ; VEGF ; Inhibitoren ; Ranibizumab ; Bevacizumab ; Rubeosis iridis ; Neovascular glaucoma ; Vascular endothelial growth factor inhibitor ; Ranibizumab ; Bevacizumab
• 刊名：Der Ophthalmologe
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：112
• 期：4
• 页码：346-352
• 全文大小：577 KB
• 参考文献：1.Altintas AG, Arifoglu HB, Tutar E et al (2012) Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in neovascular glaucoma. Cutan Ocul Toxicol 31:124-27View Article PubMed
  2.Chang YS, Tseng SY, Tseng SH et al (2006) Triamcinolone acetonide suspension toxicity to corneal endothelial cells. J Cataract Refract Surg 32:1549-555View Article PubMed
  3.Hagenah M, Halberstadt M, Wehming S et al (1996) Hydroxy?thylst?rke als Entquellungssubstanz in Kurzzeitkulturmedien für Spenderhornh?ute. Klin Monatsbl Augenheilkd 208:107-11View Article PubMed
  4.Hirsch JG, Fedorko ME (1968) Ultrastructure of human leukocytes after simultaneous fixation with glutaraldehyde and osmium tetroxide and ?postfixation-in uranyl acetate. J Cell Biol 38:615-27View Article PubMed Central PubMed
  5.Hosny MH, Zayed MA, Shalaby AM et al (2009) Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation. J Ocul Pharmacol Ther 25:513-17View Article PubMed
  6.Kinzel R (2008) Die postmortalen Ver?nderungen des Schweinehornhautendothels in Abh?ngigkeit von der Zeit. Greifswald, Univ., Med. Fak., 72 Seiten
  7.Lim TH, Bae SH, Cho YJ et al (2009) Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol 23:188-92View Article PubMed Central PubMed
  8.Lucke K, Bopp S (1998) Intraokul?re Eingriffe bei Augen mit Rubeosis iridis und Neovaskularisationsglaukom. Ophthalmologe 95:514-28View Article PubMed
  9.Naumann GOH, Apple DJ, Deuble-Bente K et al (1997) Retinale Neovaskularisationen. In: Doerr W, Seifert S (Hrsg) Pathologie des Auges II, 2.?Aufl. Springer, Berlin, S?1014-021
  10.Park HY, Kim SJ, Lee HB et al (2008) Effect of intracameral bevacizumab injection on corneal endothelium in rabbits. Cornea 27:1151-155View Article PubMed
  11.Pollmann TO (2009) Organkultivierung von tief stromal lamellierten Hornh?uten. Hannover, Med. FH, 87 Seiten
  12.Rothbaum M, Springs C (2005) The effect of preserved and preservative-free triamcinolone on corneal endothelial cells. Invest Ophthalmol Vis Sci 46:4522 (E-Abstract)
  13.Agostini H, Funk J (2004) Neovaskul?res Glaukom. In: Schlote T, Rohrbach JM (Hrsg) Sekund?rglaukome -komplizierte Glaukome in Theorie und Praxis, 1.?Aufl. Schattauer, Stuttgart, S?237-48
  14.Shin JP, Lee JW, Sohn BJ et al (2009) In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation. J Glaucoma 18:589-94View Article PubMed
  15.Sutter FK, Gillies MC (2003) Peudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 87(8):972-74View Article PubMed Central PubMed
  16.Virtanen J, Uusitalo H, Palkama A et al (1984) The effect of fixation on corneal endothelial cell dimensions and morphology in scanning electron microscopy. Acta Ophthalmol (Copenh) 62:577-85
  17.Wolf A, Jagow B von, Ulbig M et al (2011) Intracameral injection of bevacizumab for the treatment of neovascular glaucoma. Ophthalmologica 226:51-6View Article PubMed
  18.Wollweber L, Stracke R, Gothe U (1981) The use of a simple method to avoid cell shrinkage during SEM preparation. J Microsc 121:185-89View Article PubMed
  19.Yoeruek E, Spitzer MS, Tatar O et al (2007) Safety profile of bevacizumab on cultured human corneal cells. Cornea 26:977-82View Article PubMed
  20.http://www.bbraun.de/documents/Knowledge/3969050_Fluessigkeitstherapie_Zander_dt_05_09.pdf. Zugegriffen: 16. M?rz 2013
  
• 作者单位：A. Wilhelm (1)
  R. Sietmann (2)
  U. Wilhelm (3)
  T. Hammer (4)
  
  1. Augenabteilung, St. Franziskus-Hospital Münster, Hohenzollernring 74, 48145, Münster, Deutschland
  2. Ernst-Moritz-Arndt-Universit?t Greifswald, Greifswald, Deutschland
  3. St. Johannes-Hospital, Klinik für Augenheilkunde, Dortmund, Deutschland
  4. Augenzentrum ?Frohe Zukunft- Halle/Saale, Deutschland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Ophthalmology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-0423

文摘

Background The injection of antiangiogenic agents, such as ranibizumab (Lucentis?) and bevacizumab (Avastin?) into the anterior chamber of the eye represents a suitable alternative for treating neovascular glaucoma by reducing intraocular pressure. Objectives As the antiangiogenic substances are in direct contact with the sensitive corneal endothelium, the aim of this study was to show the effects of intracameral injection of ranibizumab and bevacizumab on this cell layer. Methods Each injection consisted of 50?μl containing either ranibizumab (0.5?mg/0.05?ml), bevacizumab (1.25?mg/0.05?ml) or triamcinolone containing benzyl alcohol (2?mg/0.05?ml) which was used as the control group. These compounds were injected into the anterior chamber of pig eyes. Afterwards the corneas were dissected, fixed, examined by a scanning electron microscopy and evaluated according to a specified score. Assessment of the endothelium was carried out by evaluating the condition of microvilli, cell borders, cell surface and cell pattern. The findings were compared to untreated corneas and those injected with 50?μl of balanced salt solution (BSS). Results The corneal endothelium exposed to the antiangiogenic substances showed only minor changes in comparison to the controls treated only with BSS. Also seen during this research was the irreversible cell damage in the control group using triamcinolone. Conclusion Ranibizumab and bevacizumab have no damaging effects on the corneal endothelium when used in the anterior chamber. They can be administered as an intracameral injection for the treatment of rubeotic secondary glaucoma. Triamcinolon containing benzyl alcohol causes severe damage to the endothelial cells of the cornea by direct contact.